Patent: 9,132,199
✉ Email this page to a colleague
Summary for Patent: 9,132,199
Title: | Reverse thermal gels and uses therefor |
Abstract: | Biodegradable triblock copolymer compositions are provided which are useful in tissue engineering and drug delivery. The copolymers are reverse thermal gels in that when heated from a lower temperature to a higher temperature, they gel. These gels are useful in drug delivery when complexed with an active agent. For example the compositions can be used for intraocular injection of active agents, such as anti-angiogenic agents for treatment of a maculopathy or retinitis. |
Inventor(s): | Friberg; Thomas R. (Pittsburgh, PA), Park; Daewon (Pittsburgh, PA), Wang; Yadong (Allison Park, PA) |
Assignee: | University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) |
Application Number: | 13/581,518 |
Patent Claims: | see list of patent claims |
Details for Patent 9,132,199
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2030-03-05 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2030-03-05 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2030-03-05 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2030-03-05 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2030-03-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |